Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent versus continuous paclitaxel plus bevacizumab in HER2-negative advanced breast cancer
NL-OMON45073Phase 3Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Dec 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel, bevacizumab, doxorubicin and capecitabine in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Overall progression-free survival in first-line treatment. Started Dec 2010; status: active, not recruiting.
02
Drugs
paclitaxelbevacizumabdoxorubicincapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON45073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45073.